Background The global drug control landscape is undergoing remarkable change. Many jurisdictions around the world, including jurisdictions in the United States, have decriminalized the possession and use of plant- and fungus-based psychedelics, such as psilocybin-containing mushrooms (PCM). With ORS475 A, Oregon has gone a step further by becoming the first ...
In recent years, there has been considerable enthusiasm among research groups focused on developing novel therapies for treatment-resistant depression, and a wider community that has had experiences using recreational drugs, in more systematic evaluation of the therapeutic value of these compounds (Goodwin et al., 2022; Young, 2023). This has also been assoc...
Depression remains one the most commonly diagnosed mental health disorders in the United States. The Food and Drug Administration granted psilocybin breakthrough therapy status four years ago as a possible solution to this pervasive disorder. Since then, psilocybin, and hallucinogens in general, have produced promising results as alternatives to classical an...
Back to table of contents Previous article Next article Clinical & ResearchFull AccessAustralia Legalizes Psychedelics for Use in Depression, PTSD TherapyNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:15 Aug 2023https://doi.org/10.1176/appi.pn.2023.09.9.20AbstractThe country is the first to make psilocybin and MDMA available ...
Abstract Background: Body Image Disturbance (BID) is the distorted experience of one’s body. BID presents a risk for the onset, maintenance and relapse of body dysmorphic disorder and eating disorders, including anorexia nervosa (AN). Current treatments tend to focus on the cognitive and behavioural aspects while overlooking the perceptual symptoms and BID f...
Abstract Psilocybin, a naturally occurring, tryptamine alkaloid prodrug, is currently being investigated for the treatment of a range of psychiatric disorders. Preclinical reports suggest that the biological effects of psilocybin-containing mushroom extract or “full spectrum” (psychedelic) mushroom extract (PME), may differ from those of chemically synthesiz...
Abstract Background Psilocybin-containing mushrooms induce antidepressant and momentary increase in blood pressure (BP) with potential risk to users with cardiovascular diseases. Irregularities in nitric oxide (NO) levels play a key role in endothelial dysfunctions leading to increases in BP. Mushrooms species show large variation in potency which may potent...
Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT2A receptor (5-HT2A) activation. Recent studies have revealed that serotonergic psychedelics have therapeutic potential for neuropsychiatric disorders, including major depressive and anxiety-related disorders. However, the invo...
Substances that change the states of consciousness have been used in the therapeutics of traditional cultures for hundreds of years. In the Western cultural circle, scientific curiosity and hope for a breakthrough in the treatment of various mental disorders constituted the basis of the first wave of research on humans with the use of psychedelics. After syn...
The efficacy of psilocybin and other psychedelics as modes of treatment have been demonstrated through clinical trials and other studies in the management of a number of mental illnesses, including some treatment resistant cases. In Psychedelic Assisted Psychotherapy (PAP), psychedelics catalyze or enhance the experience fostered by psychotherapeutic methods...
Back to table of contents Previous article Next article Annual MeetingFull AccessExperts Offer Tips on Talking With Patients About PsychedelicsTerri D’ArrigoTerri D’ArrigoSearch for more papers by this authorPublished Online:28 Jun 2023https://doi.org/10.1176/appi.pn.2023.07.7.51AbstractPsychedelics differ from one another in their mechanism of action and po...
Abstract Psilocybin is the psychoactive substance contained in the psilocybe(hallucinogenic) mushroom, which has received considerable attention among the scientific community in recent years. Human studies have demonstrated that even a single-dose of psilocybin can improve debilitating physical and psychological symptoms with durable long-term effects. >136...
Psychedelic fungi have received considerable attention recently due to their promising treatment potential of several psychiatric disorders and medical conditions, both in clinical settings but also as a nutraceutical. Besides research, a growing number of companies are developing capacity to conduct research and clinical trials where these fungi and their p...
Psychedelic fungi have received considerable attention recently due to their promising treatment potential of several psychiatric disorders and medical conditions, both in clinical settings but also as a nutraceutical. Besides research, a growing number of companies are developing capacity to conduct research and clinical trials where these fungi and their p...
Case report of a patient with GAD and claustrophobia who underwent exposure therapy using psilocybin-assisted psychotherapy. The patient had failed to respond to conventional psychotherapeutic treatment. After three sessions of psilocybin-assisted psychotherapy, the patient experienced a reduction in anxiety and fear associated with closed spaces, elevators,...
Several studies have been conducted and more are underway examining psilocybin-assisted therapy as a treatment for various psychiatric conditions including depressive disorders, anxiety disorders, and alcohol use disorder. However, many studies have been limited by small sample size and have not comprehensively evaluated treatment risks outside of controlled...
In 1970, the United States Drug Enforcement Administration passed the Controlled Substances Act. This statute classified and banned a variety of drugs including psilocybin, the psychoactive component found in Psilocybe Cubensis (also known as "Magic Mushrooms"). Though psilocybin was known to possess many medical benefits and cause no serious side effects, t...
Purpose of reviewThis review article summarizes clinically and socially relevant developments over the past five years in the therapeutic use of the classical tryptamine psychedelic substance psilocybin, with respect to the common challenges faced by palliative care patients and their care teams. Psilocybin is available in whole fungal and isolated forms but...
